292 followers
RT @DrugSafetyJ: FDA to investigate risk of Pulmonary Embolism/death with higher dose of #tofacitinib (#Xeljanz) in #rheumatoidarthritis pa…
374 followers
RT @DrugSafetyJ: FDA to investigate risk of Pulmonary Embolism/death with higher dose of #tofacitinib (#Xeljanz) in #rheumatoidarthritis pa…
2,614 followers
RT @DrugSafetyJ: FDA to investigate risk of Pulmonary Embolism/death with higher dose of #tofacitinib (#Xeljanz) in #rheumatoidarthritis pa…
1,025 followers
FDA to investigate risk of Pulmonary Embolism/death with higher dose of #tofacitinib (#Xeljanz) in #rheumatoidarthritis patients https://t.co/fdIWZgkw18 . Relevant 2018 𝘿𝙧𝙪𝙜 𝙎𝙖𝙛𝙚𝙩𝙮 articles https://t.co/mSxULbpU3s, https://t.co/8EhHkS8F4v, https://t.co/bf6
121 followers
RT @StefanSiebert1: JAK inhibitors and thrombotic events - especially pulmonary. Review of FDA safety data https://t.co/yZgYfzOwV1 with exc…
2,348 followers
RT @StefanSiebert1: JAK inhibitors and thrombotic events - especially pulmonary. Review of FDA safety data https://t.co/yZgYfzOwV1 with exc…
21,691 followers
RT @StefanSiebert1: JAK inhibitors and thrombotic events - especially pulmonary. Review of FDA safety data https://t.co/yZgYfzOwV1 with exc…
817 followers
RT @StefanSiebert1: JAK inhibitors and thrombotic events - especially pulmonary. Review of FDA safety data https://t.co/yZgYfzOwV1 with exc…
8,123 followers
RT @StefanSiebert1: JAK inhibitors and thrombotic events - especially pulmonary. Review of FDA safety data https://t.co/yZgYfzOwV1 with exc…
1,471 followers
RT @StefanSiebert1: JAK inhibitors and thrombotic events - especially pulmonary. Review of FDA safety data https://t.co/yZgYfzOwV1 with exc…
2,705 followers
JAK inhibitors and thrombotic events - especially pulmonary. Review of FDA safety data https://t.co/yZgYfzOwV1 with excellent commentary @RheumNow week in Review newsletter https://t.co/cj2UaRnrNn